SCHEMBL5651526

SCHEMBL5651526

CN(Cc1ccccc1)CC1CCNCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.56
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
BLM P54132 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
EP300 Q09472 1/20 0.43
CARM1 Q86X55 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
PRMT8 Q9NR22 1/20 0.43
TSHR P16473 2/20 0.42
USP2 O75604 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
PYCR1 P32322 1/20 0.42
USP30 Q70CQ3 1/20 0.42
HTR2C P28335 1/20 0.41
SIGMAR1 Q99720 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26668497 0.91 EP300 (0.46) GBA1SLC6A2SLC6A4EP300USP30
SCHEMBL14045705 0.88 ALDH1A1 (0.52) ALDH1A1LMNABLMSMN1; SMN2CARM1
SCHEMBL5650751 0.84 EP300 (0.42) GBA1SLC6A2SLC6A4ALDH1A1SMN1; SMN2
SCHEMBL784929 0.84 GBA1 (0.53) GBA1SLC6A2SLC6A4ALDH1A1CARM1
SCHEMBL16826120 0.84 PYCR1 (0.45) GBA1SLC6A2SLC6A4ALDH1A1EP300
SCHEMBL5649396 0.84 GBA1 (0.53) GBA1SLC6A2SLC6A4SIGMAR1
SCHEMBL17887965 0.84 SLC6A2 (0.52) SLC6A2SLC6A4EP300PYCR1
SCHEMBL522763 0.83 SLC18A3 (0.49) ALDH1A1LMNABLMSMN1; SMN2CARM1
SCHEMBL5119405 0.83 GBA1 (0.59) GBA1SLC6A2SLC6A4MAOAMAOB
SCHEMBL31381408 0.83 EP300 (0.41) GBA1SLC6A2SLC6A4EP300USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL GBA1 451/4885SLC6A2 4622/4885SLC6A4 4673/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL GBA1 474/4885SLC6A2 4264/4885SLC6A4 4366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.